Companies: 10,795·Total market cap: $144.5T

Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

PRLDNASDAQHealthcare● Active

$3.99

+$0.15(+3.91%)

Market Cap$227161780

P/E Ratio—

52W High$5.54

52W Low$0.75

Avg Volume384K

Open$3.87

Beta1.01

Prelude Therapeutics Incorporated (PRLD) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

PRLD · net income · updated Jun 9, 2026

Core profitability metrics

PRLD · net income · margin · TTM · CAGR

Net income was −$99.5M for FY2025 (fiscal year ending 2025-12-31), up 21.8% year-over-year. Net profit margin was -819.6%.

FY2025 Net Income−$99.5M▲ +21.8% YoY

Trailing 12M (TTM)−$77.8Mtrailing 4 quarters sum

Net Profit Margin-819.6%−$99.5M ÷ $12.1M

YoY Change+21.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · PRLD net income history · PRLD profit margin

Annual net income data

PRLD · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$99.5M▲ +21.8%-819.6%$12.1M

FY2024Loss−$127.2M▼ 4.4%-1816.8%$7.0M

FY2023Loss−$121.8M▼ 5.5%—$0

FY2022Loss−$115.4M▼ 3.4%—$0

FY2021Loss−$111.7M▼ 96.2%—$0

Net income vs peers (Healthcare)

PRLD vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Prelude Therapeutics IncorporatedYOU

PRLD

−$99.5M+21.8%-819.6%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Prelude Therapeutics Incorporated (PRLD) reported net income of −$99.5M for FY2025 (fiscal year ending 2025-12-31), up 21.8% year-over-year. The net profit margin was -819.6% — meaning the company kept $-8.20 of every dollar of revenue as profit.

Prelude Therapeutics Incorporated has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

Prelude Therapeutics Incorporated's net profit margin was -819.6% for FY2025, based on the latest annual results.

Investors sometimes search for "Prelude Therapeutics Incorporated net worth" — the company's market capitalization is a separate figure from PRLD net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

PRLD net income · 4 questions

Prelude Therapeutics Incorporated is not currently profitable on an annual basis. The company reported a net loss of $99.5M for FY2025.

is PRLD profitabledoes PRLD make a profitPRLD profitabilityPRLD profitable company

▸ Source: FMP /income-statement · GAAP · Prelude Therapeutics Incorporated · Prelude Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026